Toho Pharmaceutical plans to export Japan-made generic injectable drugs to the U.S. as early as 2028. CEO Yoshida stated that the company aims to gain a foothold in the U.S. market leveraging its advanced quality control capabilities, and will gradually shift toward high-value-added injectable drugs.